Clinical Trials

Enrolling Trials

31-40  of  159
A231601CD, Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)
Sharma, Rohit
Cancer Supportive Care
Adult
This trial studies how well the use of a pre-surgical toolkit (OPTI-Surg) works in improving surgical care and outcomes in older participants with cancer. In many elderly patients, surgery can greatly affect physical condition and the ability to return to pre-surgery levels of physical functioning. Providing pre-surgical recommendations may help improve participants' recovery rate and functioning after surgery.
Adam, Iddrisu
Bello, Tolulope O
(715) 221-7267
Carder, Margaret E
(715) 295-3048
Craig, Chani L
(715) 358-1838
Hurley, Alexa A
(715) 393-1019
Revels, Cheryl M
(715) 389-4177
Strand, Diana D
(715) 221-8353
Wilson, Anna E
(715) 858-6860
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
AALL1731, A Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Manalang, Michelle
Blood - ALL - Acute Lymphocyctic
Lymph Gland - Non-Hodgkin's
Child, Adult
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with or without Down syndrome and newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma. Monoclonal antibodies, such as blinatumomab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexate, cytarabine, mercaptopurine, doxorubicin, cyclophosphamide, and thioguanine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin decreases the toxic effects of methotrexate. Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. Giving blinatumomab and combination chemotherapy may work better then combination chemotherapy alone in treating patients with B-ALL. This trial also assigns patients into different chemotherapy treatment regimens based on risk (the chance of cancer returning after treatment). Treating patients with chemotherapy based on risk may help doctors decide which patients can best benefit from which chemotherapy treatment regimens.
Revels, Cheryl M
(715) 389-4177
Strand, Diana D
(715) 221-8353
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Manalang, Michelle
Blood - ALL - Acute Lymphocyctic
Child, Adult
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, in order to classify patients into post-consolidation treatment groups. On the second part of this study, patients will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Dietel, Melissa B
(715) 221-7272
Schillinger, Debra D
(715) 387-9521
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Fagbemi, Seth O
Bladder, Prostate, Kidney - Prostate
Adult
To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can improve PFS compared to abiraterone acetate alone.
Revels, Cheryl M
(715) 389-4177
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
ACCRU-SC-1601, A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Onitilo, Adedayo A
Cancer Supportive Care
Adult
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related blood clots in cancer patients who have completed anticoagulation therapy. Apixaban may stop the clotting of blood by blocking some of the enzymes needed for blood clotting.
Carder, Margaret E
(715) 295-3048
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Marshfield Clinic Research Institute
1000 N OAK AVE
Marshfield, WI  54449
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
ACNS1723, A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Manalang, Michelle
Brain, Spinal Cord - Brain Primary
Child
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib after radiation therapy may work better than treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade glioma.
Dietel, Melissa B
(715) 221-7272
Schillinger, Debra D
(715) 387-9521
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
AFT-19, A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Fagbemi, Seth O
Bladder, Prostate, Kidney - Prostate
Adult
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time = 9 months at the time of study entry.
Hurley, Alexa A
(715) 393-1019
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Clinic Research Institute
1000 N OAK AVE
Marshfield, WI  54449
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
AHEP1531, Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
McManus, Michael J
Liver Tumors
Child
This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy may kill more tumor cells than one type of chemotherapy alone.
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Manalang, Michelle
Treatment of Side Effects
Child
Neuropsychological and behavioral assessments are a crucial component of monitoring for late effects in patients being treated, normally quite aggressively, for cancer. This is especially true for patients that are exposed to potentially neurotoxic therapies. However, lack of compliance with assessment schedules, variations in assessment schedules and neuropsychological measures utilized across studies, as well as overly complex and long neuropsychological assessments have proved to be problematic to the assessment process within the Children's Oncology Group (COG). In order to remediate these problems, a streamlined and standardized neuropsychological and behavioral assessment battery has been developed. The COG Standard Neuropsychological and Behavioral Battery is a focused assessment of critical functional domains that have been empirically shown to be most affected by childhood cancer, its treatment, or other disease related factors. This battery was designed to provide a brief measure of neuropsychological and behavioral function in order to strike a balance between research goals, the clinical needs of the patient, and time constraints on the institutional neuropsychologist/psychologist. The battery of tests will take only about 1 hour to administer and all patients will be tested at 3 standardized timepoints. Parent-completed questionnaires will also be utilized to gather information about the patient's function, specifically in terms of attention, memory, executive abilities, and behavioral/social/emotional adaptation.
Welter, Stacy L
(715) 221-6492
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
ANBL00B1, Neuroblastoma Biology Studies
Manalang, Michelle
Biology
Child
The objectives of the study are to prospectively analyze the factors that are currently used for risk-group assignment (NDA content by flow cytometry, MYCN copy number by FISH, and tumor histology using the International Neuroblastoma Pathologic Classification System) in neuroblastoma tumors at the time of diagnosis. To maintain a reference bank containing clinical and genetically characterized frozen tumor tissue, tumor DNA and RNA, tumor touch perpetration, histology slides and blocks, cell lines, and paired normal DNA obtained at the time of diagnosis (all patients), at the time of second-look surgery (high-risk patients), and relapse (all patients) for future research studies. To prospectively analyze the prevalence of 1p, 11q, 14q LOH and gain of 17q; the expression of nerve growth factor (NGF) and its high affinity (Trk-A) and low affinity (p75NTR) receptors; and telomerase activity in diagnostic neuroblastoma tumors, and to determine the independent clinical significance of these biologic factors compared to MYCN amplification, INSS stage, age, and histologic variables in predicting either response to treatment or outcome. To build a database of the known biologic prognostic factors for patients on therapeutic studies. Adjustment for, or stratification by, these prognostic factors will be performed when testing for treatment effect in Phase III trials.
Welter, Stacy L
(715) 221-6492
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449